As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against the variant.
On Tuesday, Regeneron sounded (PDF) a disquieting alarm bell, saying its successful COVID-19 antibody treatment may not work against the elusive new strain. For his part, Moderna CEO Stéphane Bancel predicted a “material drop” in mRNA vaccine efficacy.
